Riskpilot← Back to searchSign inGet full accessNormedi AB
ABActiveOrg 5569584179SolnaWholesale of pharmaceutical and medical goods · NACE 4646Est. 20146 employees
Revenue 2025
SEK 85,1M
+9% vs 2024
EBITDA margin
5.8%
+111% vs 2024
Equity ratio
32.5%
Financial strength
Net profit 2025
SEK 3,5M
+115% vs 2024
| Revenue | SEK 85,1M | +9% |
| EBITDA | SEK 5M | +111% |
| Net profit | SEK 3,5M | +115% |
| Total assets | SEK 28,4M | -3% |
| Equity | SEK 9,2M | +63% |
| Employees | 6 | — |
Legal name
Normedi AB
Org number
5569584179
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14 januari 2014
Share capital
SEK 50 000
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-09-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Steffensen, Jesper
Company purpose
Bolaget ska sälja och marknadsföra medicintekniska produkter och bedriva därmed förenlig verksamhet.
Address
Solna
Email
rebecka@normedi.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 44 222 | 58 282 | 47 501 | 78 250 | 85 117 |
| Staff expenses | — | — | — | — | −8 669 |
| EBITDA | 3 684 | 3 453 | 1 389 | 2 358 | 4 966 |
| Depreciation & amort. | −228 | −286 | −152 | −339 | −538 |
| EBIT | 3 456 | 3 167 | 1 237 | 2 019 | 4 428 |
| Net financials | 205 | 231 | 354 | 77 | 84 |
| Profit before tax | 3 662 | 3 398 | 1 591 | 2 095 | 4 512 |
| Tax | −766 | −717 | −331 | −443 | −963 |
| Net profit | 2 896 | 2 681 | 1 260 | 1 652 | 3 549 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 19 878 | 24 143 | 27 468 | 29 190 | 28 392 |
| Equity | 3 384 | 2 765 | 4 024 | 5 676 | 9 225 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 16 494 | 21 379 | 23 443 | 23 514 | 19 167 |
| Total debt | 16 494 | 21 379 | 23 443 | 23 514 | 19 167 |
EBITDA margin
5.8%
This company
15.8%
Market median
-63% vs market
20212025
Equity ratio
32.5%
This company
38.2%
Market median
+15% vs market
20212025
Return on equity
38.5%
This company
18.4%
Market median
+109% vs market
20212025
Net profit margin
4.2%
This company
8.1%
Market median
-48% vs market
20212025
Asset turnover
3.00×
This company
1.12×
Market median
+168% vs market
20212025
Debt / equity
2.08×
This company
0.62×
Market median
-235% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-09-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
BL Chief Auditor | Chief Auditor | 2020 |
JS Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (1) | ||
GN Chief Executive Officer | Chief Executive Officer | 2020 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2025 | |
| Deputy Board Member | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 | |
| Company | 100% | 100% | 2026 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HOLOGIC GGO 4 LTD
Normedi AB (this company)Board members of Normedi AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Barbro Linnéa Karlsson | Chief Auditor | 0 companies |
| Jesper Steffensen | Chief Executive Officer | 0 companies |
| Granne Norling Öystein | Chief Executive Officer | 0 companies |
| Michelangelo Stefani | Chairman | 0 companies |
| Joao Paulo Falcao Malagueira | Deputy Board Member | 0 companies |